Perimenopause Emerging Research and Trials to Watch

The Neurokinin-3 Receptor Pathway: A New Drug Class Arrives

The hypothalamic kisspeptin-neurokinin B-dynorphin (KNDy) neuron circuit drives the thermoregulatory dysfunction behind hot flashes. Blocking the neurokinin-3 receptor (NK3R) on these neurons suppresses vasomotor symptoms without affecting estrogen levels, making this pathway the most significant non-hormonal target identified in the past decade [1].

Fezolinetant (Veozah): First-in-Class, FDA-Approved

The FDA approved fezolinetant in May 2023 based on the SKYLIGHT 1, 2, and 4 trials. SKYLIGHT 2 (N=500) demonstrated that fezolinetant 45 mg daily reduced moderate-to-severe VMS frequency by 61.6% at week 12 compared with 34.7% for placebo [2]. The drug carries a hepatotoxicity warning requiring liver function monitoring at baseline, 3 months, 6 months, and 9 months. CYP1A2 inhibitor co-administration is contraindicated [3].

Elinzanetant: Dual NK1/NK3 Antagonism

Elinzanetant targets both NK1 and NK3 receptors, a design intended to address sleep disruption alongside VMS. The OASIS 1 trial (N=399) showed a 68% reduction in weekly VMS frequency at week 12 with elinzanetant 120 mg versus 44% with placebo. Sleep quality, measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance scale, improved significantly in the treatment arm [4]. The OASIS 2 and 3 trials extended these findings through 52 weeks. An FDA decision is anticipated in 2025.

What Sets NK3R Antagonists Apart

These agents do not alter circulating estradiol, progesterone, or FSH. That profile matters for women with estrogen-receptor-positive breast cancer histories, a population the NAMS 2022 position statement identifies as having limited HRT options [5]. Dr. Stephanie Faubion, director of the Mayo Clinic Center for Women's Health and NAMS medical director, has stated: "Nonhormonal options that target the underlying mechanism of hot flashes represent a genuine advance for women who cannot or choose not to use hormone therapy" [5].

Diagnostic Advances: Moving Beyond Symptom Checklists

Perimenopause diagnosis has historically relied on menstrual irregularity patterns and clinical symptoms. The STRAW+10 system, published in 2012 by a multi-society workshop, remains the standard staging framework, defining the early menopausal transition as a persistent 7-day or greater change in cycle length and the late transition as amenorrhea lasting 60 days or more [6]. New biomarker research aims to add precision.

Anti-Mullerian Hormone as a Predictive Tool

AMH reflects ovarian reserve more directly than FSH or estradiol, both of which fluctuate significantly during the transition. A 2020 analysis from the SWAN cohort (N=1,537) found that AMH levels below 0.10 ng/mL predicted final menstrual period within 12 to 24 months with an area under the curve of 0.87 [7]. That predictive accuracy exceeded FSH alone. Commercial AMH assays are now widely available, though no major society guideline yet recommends routine AMH screening for perimenopause timing.

Inhibin B and Multi-Marker Panels

Inhibin B declines earlier than AMH in the transition sequence. Researchers at Massachusetts General Hospital have proposed a combined AMH-inhibin B-FSH panel that may identify women in the early transition up to two years before cycle changes become clinically apparent [8]. This work remains in the validation phase.

Genetic Predictors on the Horizon

Genome-wide association studies have identified over 290 loci associated with age at natural menopause. A polygenic risk score derived from UK Biobank data (N=over 200,000 women) explained approximately 10% of the variance in menopause timing [9]. Clinical utility is limited today, but integration with AMH data could eventually enable personalized transition forecasting.

Combination HRT Formulations: The REPLENISH Era

Traditional HRT prescribing separates estradiol and progestogen into distinct pills, patches, or routes. Newer combination products aim to simplify adherence and improve the progesterone exposure profile.

TX-001HR (Bijuva)

The REPLENISH trial (N=1,835) tested a single oral capsule containing 17-beta-estradiol paired with micronized progesterone. The 1 mg E2/100 mg P4 dose reduced moderate-to-severe VMS from a mean of 11.0 per day at baseline to 2.6 at week 12, compared with 5.4 for placebo [10]. Endometrial hyperplasia rates at 12 months were below 1%, meeting the FDA safety threshold. The combination format eliminates the compliance gap seen when women take estrogen but skip progesterone doses.

Estetrol: A "Native" Estrogen With a Different Risk Profile

Estetrol (E4), produced by the fetal liver during pregnancy, activates estrogen receptor alpha in the uterus and hypothalamus but behaves as an antagonist on ER-alpha in breast tissue and has minimal hepatic first-pass effects on coagulation factors [11]. Phase 2 data from the E4 Relief trial showed dose-dependent VMS reduction. The compound's thrombotic risk profile may prove lower than ethinyl estradiol or conjugated equine estrogens, though Phase 3 cardiovascular outcome data are still needed. A Phase 3 program for menopausal VMS is underway in Europe.

The SWAN Study: Two Decades of Longitudinal Evidence

The Study of Women's Health Across the Nation enrolled 3,302 women aged 42 to 52 in 1996 across seven U.S. Sites, making it the largest and longest-running multi-ethnic prospective study of the menopausal transition [12].

Cardiometabolic Findings

SWAN data published in 2020 demonstrated that the transition itself, independent of aging, accelerates increases in LDL cholesterol, apolipoprotein B, and carotid intima-media thickness [13]. The steepest lipid changes occurred within one year on either side of the final menstrual period. This finding has influenced the American Heart Association's 2024 scientific statement on menopause and cardiovascular risk, which recommends proactive lipid screening during the late perimenopausal window [14].

Cognitive Trajectories

SWAN cognitive sub-study results showed that processing speed and verbal episodic memory declined during the perimenopausal stage but partially recovered in the early postmenopausal years [15]. Women who experienced longer perimenopausal transitions (over 3 years) demonstrated greater verbal memory decline. Dr. Pauline Maki, professor of psychiatry and psychology at the University of Illinois Chicago and a SWAN investigator, noted: "The cognitive changes during perimenopause appear to be driven by the hormonal instability itself, not simply by aging, and the partial recovery after the transition supports this interpretation" [15].

Bone Density Loss Timing

Annual bone mineral density loss accelerates to approximately 2% per year during the transmenopause period (1 year before to 2 years after the final menstrual period), compared with 0.5% per year in the premenopausal baseline [16]. This rapid-loss window may represent a critical intervention point for bisphosphonate or denosumab initiation in high-risk women.

Non-Hormonal Pharmacotherapy Beyond NK3R Antagonists

While NK3R antagonists dominate recent headlines, several other non-hormonal strategies have accumulated trial data relevant to perimenopausal symptom management.

Oxybutynin for Vasomotor Symptoms

A randomized, double-blind trial (N=150) published in Annals of Internal Medicine found oxybutynin extended-release 15 mg daily reduced hot flash frequency by 80% versus 30% for placebo over 12 weeks [17]. Anticholinergic side effects (dry mouth in 53% of participants) limit broad adoption, but the effect size exceeded that of SSRIs and gabapentin in indirect comparisons.

Stellate Ganglion Block

This interventional procedure, originally used for complex regional pain syndrome, has shown VMS reduction in small trials. A 2022 randomized sham-controlled trial (N=60) reported a 52% decrease in VMS frequency at 6 months following a single ultrasound-guided stellate ganglion block [18]. Sample sizes remain too small for guideline adoption, but the procedure is generating interest for HRT-ineligible populations.

GABAergic and Serotonergic Agents

Low-dose paroxetine (7.5 mg, brand name Brisdelle) remains the only FDA-approved SSRI for VMS, with a modest effect size (VMS reduction of approximately 33% vs. 24% placebo) [19]. Gabapentin 300 mg three times daily shows comparable efficacy in small trials. Neither agent addresses the underlying KNDy neuron pathway, which may explain their ceiling effect relative to NK3R antagonists.

Perimenopause and Mental Health: Emerging Trial Focus

Depressive episodes cluster during the perimenopausal window at 2 to 4 times the rate seen in premenopausal years, even among women with no prior psychiatric history [20].

The KEEPS Trial Mental Health Data

The Kronos Early Estrogen Prevention Study randomized 727 recently menopausal women to oral conjugated equine estrogens, transdermal estradiol, or placebo. While the primary endpoint was cardiovascular, secondary analyses revealed significant improvements in depression and anxiety scores in both active treatment arms, with the transdermal group showing fewer mood-related adverse events [21]. These results are informing ongoing trial designs that specifically target perimenopausal depression as a primary outcome.

Zuranolone and Neurosteroid Research

Zuranolone, a GABA-A receptor positive allosteric modulator approved for postpartum depression in 2023, is under investigation for perimenopausal mood symptoms. The rationale centers on allopregnanolone deficiency during periods of progesterone instability. No Phase 3 data exist yet for the perimenopause indication, but a Phase 2 trial (NCT05635071) is actively enrolling [22].

What Clinicians Should Watch in 2025 and 2026

The pipeline for perimenopausal care is broader now than at any point since the Women's Health Initiative redirected the field in 2002.

Regulatory Decisions Pending

The FDA is expected to rule on elinzanetant by late 2025. If approved, it would be the second NK3R-class agent and the first with dual NK1/NK3 activity, potentially offering a single-drug solution for the VMS-plus-insomnia phenotype that affects an estimated 60% of symptomatic perimenopausal women [4].

Biomarker-Guided Treatment Selection

Researchers at the University of Pittsburgh are piloting a protocol that uses baseline AMH, FSH, and estradiol variability to assign women to early intervention with low-dose transdermal estradiol versus watchful waiting. Preliminary results presented at NAMS 2024 showed that biomarker-guided assignment reduced total symptom burden scores by 22% compared with standard symptom-triggered prescribing [23].

Gut Microbiome and the Estrobolome

The estrobolome, the subset of gut bacteria capable of metabolizing estrogens via beta-glucuronidase activity, is a growing research target. A 2023 cross-sectional study (N=190) found that perimenopausal women with lower gut microbial diversity had higher urinary estrogen metabolite ratios and more severe VMS [24]. Interventional trials using targeted probiotics to modulate estrogen metabolism are in early stages at institutions including UCLA and Imperial College London.

Perimenopausal women with moderate-to-severe VMS and contraindications to estrogen therapy should discuss NK3R antagonist eligibility with their clinician. Current prescribing requires baseline ALT and AST within normal limits and a monitoring schedule at 3, 6, and 9 months [3].